SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-137068
Filing Date
2022-05-03
Accepted
2022-05-02 17:36:00
Documents
16
Period of Report
2022-05-02
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d250478d8k.htm   iXBRL 8-K 34633
2 EX-10.1 d250478dex101.htm EX-10.1 14085
3 EX-10.2 d250478dex102.htm EX-10.2 16507
4 EX-99.1 d250478dex991.htm EX-99.1 9608
  Complete submission text file 0001193125-22-137068.txt   269061

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA bcacu-20220502.xsd EX-101.SCH 4847
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bcacu-20220502_def.xml EX-101.DEF 14859
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcacu-20220502_lab.xml EX-101.LAB 25174
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcacu-20220502_pre.xml EX-101.PRE 15952
10 EXTRACTED XBRL INSTANCE DOCUMENT d250478d8k_htm.xml XML 7309
Mailing Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017
Business Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017 6466036716
Brookline Capital Acquisition Corp. (Filer) CIK: 0001814140 (see all company filings)

IRS No.: 851260244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39488 | Film No.: 22883514
SIC: 2836 Biological Products, (No Diagnostic Substances)